Hunan Cancer Hospital
121
37
42
23
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.8%
1 terminated/withdrawn out of 121 trials
95.8%
+9.3% vs industry average
19%
23 trials in Phase 3/4
0%
0 of 23 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (121)
Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
Role: collaborator
International Collaborative Study on AJCC/UICC TNM-10 for Nasopharyngeal Cancer
Role: collaborator
A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer
Role: collaborator
Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer
Role: lead
LDRT and Chemoimmunotherapy in NPC With Liver Metastasis
Role: lead
A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors
Role: collaborator
Becotatug Vedotin as Adjuvant Therapy For High-risk Nasopharyngeal Carcinoma
Role: collaborator
Anlotinib Plus Penpulimab as Second-line Treatment for Patients With Small Cell Lung Cancer After Failure of Platinum-based Chemotherapy
Role: lead
Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma
Role: lead
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Role: collaborator
The Effectiveness and Safety of SBRT in the Treatment of Patients With MPLC After Surgery (SMILE)
Role: collaborator
A Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors
Role: lead
2 Courses of Concurrent Cisplatin Chemoradiotherapy After Surgery for High-risk Head and Neck Squamous Cell Carcinoma
Role: collaborator
Shenqi Fuwei Mixture Combined With Chemotherapy Neoadjuvant Therapy for Locally Advanced Gastric Cancer
Role: lead
Lorlatinib in ROS1+ NSCLC With Brain Metastasis
Role: lead
Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd
Role: lead
Real-World Study on CDK4/6 Inhibitors Combined With Endocrine Therapy and Subsequent Treatment in HR+/HER2- MBC.
Role: lead
Effect of Oral Nutritional Supplements on Body Weight Loss of Patients With Nasopharyngeal Carcinoma
Role: collaborator
A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors
Role: collaborator
TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
Role: collaborator